.svg){kind=small}
Market Insights Snapshot
Foy concentrated fully in Edible during May 2026, with Edible holding 100.0% share and ranking 17 in New York, while year-over-year Edible sales rose 66.6% and month-over-month declined 9.1%. The average price decreased 0.8% YoY alongside a 66.6% brand-level YoY sales gain, indicating volume is offsetting price and that the single-category focus tightened exposure to intra-month volatility; the implication is that Foy’s category purity converts pricing into throughput, but May 2026’s 9.1% MoM dip against a 17th-place rank suggests sensitivity to short-cycle demand within New York Edibles.
The mix shift is absent by design—Edible at 100.0%—so positioning hinges on price-to-volume execution rather than portfolio balance, with a 66.6% YoY sales increase against a 0.8% YoY price decline pointing to elasticity that can win share if sustained, yet the 9.1% MoM contraction and a 17 rank cap near-term climb without additional category lanes. This pattern implies Foy’s pathway is to trade modest pricing for rank gains inside Edibles while accepting higher month-to-month variance; without diversifying beyond Edible, the brand’s ceiling is tethered to its performance within the 17th slot and the ability to convert sub-1% price moves into double-digit percentage volume growth.
Competitive Landscape
Foy is currently ranked #17 in NY Edible in May 2026, a 4-position improvement from #21 in May 2025, while holding flat versus February 2026 at #17; this sits below its peak of #12 reached in June 2024 and indicates a 5-rank gap still to reclaim. Against competitors, Camino moved up from #2 to #1 YoY as its sales grew 15.9% YoY, and Off Hours slipped from #1 to #2 with 6.8% YoY growth, whereas Wyld held #3 with 25.0% YoY growth and Gron / Grön stayed at #4 with 30.2% YoY growth; this positioning implies that Foy’s 4-rank YoY rise is occurring amid faster-growing top-tier rivals and suggests its current trajectory points to mid-tier consolidation rather than a near-term return to the #12 peak absent share gains beyond the category baseline.
Notable Products
CBD/THC/CBG 1:1:1 Daytime Mango Blood Orange Chews 20-Pack (100mg CBD, 100mg THC, 100mg CBG) fell 15.2% month over month in May 2026 and sat at rank 2, while CBD/THC/CBN 1:1:1 Night Time Strawberry Adaptogen Chews 20-Pack (100mg THC, 100mg CBD, 100mg CBN) slipped 3.3% but held rank 1. In contrast, CBD/THC/CBN 1:1:1 Night Time Sleep Strawberry Chews 4-Pack (20mg THC, 20mg CBD, 20mg CBN) declined 48.6% and ranked 4, and the budget Strawberry Gummy 20-Pack (100mg) in rank 5 edged up 3.3% on low base sales of $2,547. With four of the top five SKUs in Edibles and two sleep-focused CBN formats moving in opposite directions, the mix points to reliance on flagship multi-cannabinoid packs while smaller trial sizes are volatile. The pattern implies Foy is consolidating around high-rank multipacks in Edibles as the core commercial driver, with trial-size variance signaling where pricing or promotional recalibration could steer incremental volume.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
